We found a positive correlation between the high-risk group andips-CTLA4 (−)/PD1 (−), while a negative correlation was existed between the high-risk group and ips-CTLA4 (−)/PD1 (+) and ips-CTLA4 (+)/PD1 (+) in, indicating that the PRAD model risk can influence the immunotherapy response and the high-risk group of PRAD patients had poor responses to ICIs. Here, CTLA4 is linked to prostate adenocarcinoma.